Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor-α Blockers
Authors:
- Salvatore IervolinoSISalvatore Iervolino
- Matteo Nicola Dario DI MinnoMatteo Nicola Dario DI Minno
- Rosario PelusoRPRosario Peluso
- Mariana LofranoMLMariana Lofrano
- Anna RussolilloARAnna Russolillo
- Giovanni DI MinnoGiovanni DI Minno
- Raffaele ScarpaRSRaffaele Scarpa
- 15 January 2012
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (3) , 568-573
Abstract
Objective.: To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-α (TNF-α) antagonists.Methods.: In total 146 consecutive patients with PsA eligible for anti-TNF-α therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease activity (MDA) and those who did not.Results.: Among 146 PsA subjects, 10 discontinued therapy before 3-month followup because of adverse events; thus 136 concluded the study. All clinical outcome measures changed significantly from T0 to T3. Erythrocyte sedimentation rate showed a significant reduction (p < 0.001). C-reactive protein (CRP), serum cholesterol, and triglycerides showed no significant variation (p > 0.05). The prevalence of MetS and liver steatosis showed no significant differences between subjects achieving MDA and those who did not (p = 0.347 and 0.053, respectively). Patients achieving MDA at T3 were younger than those not achieving MDA (p = 0.001). A lower baseline tender joint count (p = 0.001), swollen joint count (p = 0.013), Bath Ankylosing Spondylitis Disease Activity Index (p = 0.021), and Ritchie index (p = 0.006) were found in subjects achieving MDA. Age (OR 0.896, p = 0.003) and Bath Ankylosing Spondylitis Functional Index (BASFI) (OR 0.479, p = 0.007) inversely predicted, whereas CRP (OR 1.78, p = 0.018) directly predicted, achievement of MDA at T3.Conclusion.: In patients with PsA, age, CRP, and BASFI at the beginning of treatment were found to be reliable predictors of MDA after 3 months of TNF-α blocker therapy.Keywords
This publication has 33 references indexed in Scilit:
- Platelet Reactivity and Disease Activity in Subjects with Psoriatic ArthritisThe Journal of Rheumatology, 2011
- Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohortArthritis Care & Research, 2010
- Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial dataArthritis Care & Research, 2010
- Remission in psoriatic arthritis: is it possible and how can it be predicted?Arthritis Research & Therapy, 2010
- Time and predictors of response to tumour necrosis factor- blockers in psoriatic arthritis: an analysis of a longitudinal observational cohortRheumatology, 2010
- Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexateAnnals of the Rheumatic Diseases, 2007
- Predictors for radiological damage in psoriatic arthritis: results from a single centreAnnals of the Rheumatic Diseases, 2007
- Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis & Rheumatism, 2007
- Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitorsAnnals of the Rheumatic Diseases, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006